Akcea and Pfizer Inc. announce licensing agreement for investigative antisense therapy AKCEA-ANGPTL3-LRx
|
07 October 2019 |
Ian Read to retire as Executive Chairman of Pfizer's Board of Directors; Chief Executive Officer Dr. Albert Bourla named Chairman
|
30 September 2019 |
Pfizer invests half billion dollars to advance state-of-the-art gene therapy facility in Sanford, North Carolina
|
29 August 2019 |
The Pfizer Foundation invests in 20 organizations tackling infectious diseases and antimicrobial resistance
|
21 August 2019 |
Mylan and Upjohn, a division of Pfizer, to combine, creating a new champion for global health uniquely positioned to fulfill the world's need for medicine
|
29 July 2019 |
Pfizer completes acquisition of Therachon
|
05 July 2019 |
Jeff Settleman, Ph.D., joins Pfizer to lead Oncology Research & Development
|
07 June 2019 |
Pfizer announces top-line results from Phase 3 Trial of LYRICA® (pregabalin) in primary generalized tonic-clonic seizures
|
24 May 2019 |
Pfizer and Lilly announce top-line results from long-term Phase 3 study of tanezumab in patients with osteoarthritis
|
22 April 2019 |
Pfizer secures exclusive option to acquire gene therapy company Vivet Therapeutics
|
21 March 2019 |
Ochsner Health System and Pfizer partner to develop innovative models for clinical trials
|
19 February 2019 |
The Union for International Cancer Control and Pfizer announce new phase of global grants initiative supporting metastatic breast cancer patients
|
08 February 2019 |
Pfizer receives positive CHMP opinion for Vizimpro® (dacomitinib) for the first-line treatment of adult patients with locally advanced or metastatic non-small cell lung cancer with EGFR-activating mutations
|
01 February 2019 |
Pfizer and Lilly announce top-line results from second Phase 3 study of tanezumab in osteoarthritis pain
|
29 January 2019 |
US FDA accepts regulatory submissions for review of tafamidis to treat transthyretin amyloid cardiomyopathy
|
14 January 2019 |
Pfizer initiates phase 2b/3 clinical trial for PF-06651600, an oral JAK3 inhibitor, for the treatment of patients with moderate to severe alopecia areata
|
05 January 2019 |
Pfizer receives positive CHMP opinion for oncology biosimilar, ZIRABEV™ (bevacizumab)
|
14 December 2018 |
Pfizer reaches a global agreement with AbbVie
|
04 December 2018 |
Pfizer announces Executive Leadership Team
|
09 October 2018 |
Pfizer to award more than $3 million in grants to further breast cancer research
|
04 October 2018 |